On May 8, 2020, Quidel announced it had received Emergency Use Authorization (EUA) from the FDA to market its Sofiaﾮ 2 SARS Antigen FIA, a rapid point-of-care test to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid detection of SARS-CoV-2 in nasal or nasopharyngeal specimens from patients meeting the CDC criteria for suspected COVID-19 infection.